Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease [2]

New England Journal of Medicine

Volumn 358, Issue 7, 2008, Pages 742-743

  Papac, Rose J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORMETHINE; MUSTARD GAS DERIVATIVE; ANTINEOPLASTIC AGENT; MOPP PROTOCOL; PREDNISONE; PROCARBAZINE; UNCLASSIFIED DRUG; VINCRISTINE;

BONE MARROW HYPOPLASIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHEMICAL WARFARE; CLINICAL TRIAL; HODGKIN DISEASE; HUMAN; LETTER; PRIORITY JOURNAL; UGANDA; MULTIMODALITY CANCER THERAPY; NOTE; RADIOTHERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HODGKIN DISEASE; HUMANS; LYMPHATIC IRRADIATION; MECHLORETHAMINE; PREDNISONE; PROCARBAZINE; VINCRISTINE;

EID: 39049162529     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc073375     Document Type: Letter

References (5)

1. Infield GB. Disaster at Bari. New York: Macmillan, 1971.
2. Gilman A. The initial clinical trial of nitrogen mustard. Am J Surg 1963;105:574-8.
3. Krumbhaar EB. Role of the blood and the bone marrow in certain forms of gas poisoning. I. Peripheral blood changes and their significance. JAMA 1919;72:39-41.
4. The pathology of mustard poisoning. In: Winternitz MC. Collected studies on the pathology of war gas poisoning from the Department of Pathology and Bacteriology, medical science section, chemical warfare. New Haven, CT: Yale University Press, 1920:101-16.
5. Berenblum I. The anti-carcinogenic action of dichlorodiethylsulphide (mustard gas). J Pathol Bacteriol 1931;34:731-46.